Portfolio Acquisitions & Dossier Development

About Substipharm

Substipharm is a fast-growing, privately-held French pharmaceutical group with a dual focus on niche generic drugs and vaccines. Its business model combines in-house pharmaceutical dossier development, targeted acquisitions, and international commercialization through both direct sales and partnerships. Recent strategic moves, including the acquisition of the IMOJEV® vaccine and expansion into biologics, underscore its ambition to become a significant player in providing accessible medicines in emerging and established markets globally.

Therapeutic Areas